<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40960239</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa2511774</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks. All the patients had obesity without diabetes mellitus. The primary end point was the percent change in body weight from baseline to week 72, as assessed according to the treatment-regimen estimand in the intention-to-treat population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 3127 patients underwent randomization. The mean change in body weight from baseline to week 72 was -7.5% (95% confidence interval [CI], -8.2 to -6.8) with 6 mg of orforglipron, -8.4% (95% CI, -9.1 to -7.7) with 12 mg of orforglipron, and -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo (P&lt;0.001 for all comparisons with placebo). Among the patients in the orforglipron 36-mg group, 54.6% had a reduction of 10% or more, 36.0% had a reduction of 15% or more, and 18.4% had a reduction of 20% or more, as compared with 12.9%, 5.9%, and 2.8% of the patients, respectively, in the placebo group. Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment as compared with placebo. Adverse events resulted in treatment discontinuation in 5.3 to 10.3% of the patients in the orforglipron groups and in 2.7% of those in the placebo group. The most common adverse events with orforglipron were gastrointestinal effects, which were mostly mild to moderate.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. (Funded by Eli Lilly; ATTAIN-1 ClinicalTrials.gov number, NCT05869903.).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Massachusetts Medical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wharton</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>York University, Toronto.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wharton Weight Management Clinic, Burlington, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronne</LastName><ForeName>Louis J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefanski</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Eli Lilly, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfaris</LastName><ForeName>Nasreen F</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciudin</LastName><ForeName>Andreea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Endocrinology and Nutrition Department, Hospital Universitari Vall d'Hebron, Barcelona.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Diabetes and Metabolism Research Unit, Vall d'Hebron Institut de Recerca, Barcelona.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Physiology, Universitat Aut&#xf2;noma de Barcelona, Barcelona.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Diabetes y Enfermedades Metab&#xf3;licas Asociadas, Madrid.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Salud Carlos III, Madrid.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokote</LastName><ForeName>Koutaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Chiba University, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halpern</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0973-5065</Identifier><AffiliationInfo><Affiliation>Obesity Center, Nove de Julho Hospital, S&#xe3;o Paulo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shukla</LastName><ForeName>Alpana P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Chunmei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eli Lilly, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macpherson</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Eli Lilly, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Sheryl E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Eli Lilly, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Nadia N</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>Eli Lilly, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klise</LastName><ForeName>Suzanne R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Eli Lilly, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ATTAIN-1 Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05869903</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40960239</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2511774</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>